Loading
Latest filing published 11 Jan 2023 for Jounce Therapeutics, Inc., €4,293.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Elizabeth Trehu on record concern Jounce Therapeutics, Inc., in the capacity of senior executive. Over a trading history stretching from 5 March 2018 to 10 January 2023, the count stands at 32 filings.
On the market, this insider has only sold: 20 sales, €477k in total. Besides market trades, the filings include 5 share grants and 7 option exercises. Since January 2023: no purchases and 2 sales on the market.
On 11 January 2023 came the latest disclosure, an open-market sale for €5,349 in Jounce Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations